Sign in Subscribe
Cancer research

Cancer Gene Therapy Advances with Smart CART Nanosymbionts

Strategic Insights

— 1 min read

A new study published in the journal Frontiers in Immunology has presented a novel approach to cancer gene therapy, leveraging the convergence of artificial intelligence (AI), nanotechnology, and personalized medicine. The research, conducted by a team of scientists from ICESI University, proposes the concept of Smart CART Nanosymbionts, an integrated framework that combines AI-guided design and deployment of nanotechnology-enhanced chimeric antigen receptor T-cell (CAR-T) therapies. The study highlights the potential of this approach to overcome the limitations of current CAR-T therapy, including complex manufacturing, high costs, and limited efficacy in solid tumors.

Key Takeaways:

  • The Smart CART Nanosymbionts framework integrates AI, nanotechnology, and personalized medicine to optimize CAR-T therapy design and deployment.
  • AI plays a crucial role in guiding the design and deployment of nanotechnology-enhanced CAR-T therapies, improving patient stratification, treatment response prediction, and toxicity monitoring.
  • The research presents a transformative step forward in personalized cancer treatment, promising to advance precision, accessibility, and overall effectiveness.
  • The Smart CART Nanosymbionts framework enables optimization of lipid nanoparticle formulations for mRNA transfection, specific targeting and modification of the tumor microenvironment, and real-time monitoring of CAR-T cell behavior and toxicity.
  • The convergence of AI, nanotechnology, and personalized medicine holds strong potential for better patient outcomes in cancer treatment.

Statistics:

  • The study proposes the use of nanotechnology to improve gene delivery, target tumors more precisely, and enhance immune cell function.
  • The Smart CART Nanosymbionts framework is designed to overcome several barriers in solid tumors, including complex manufacturing, high costs, and limited efficacy.
  • The research highlights the importance of addressing ethical and regulatory considerations surrounding the emerging interface of living therapies and computational driven systems.

Sources:

  • NewsRx [1]
  • Frontiers in Immunology [2]
  • Smart CART Nanosymbionts: archetypes and proto-models. Frontiers in Immunology, 2025,16. (Frontiers in Immunology - http://journal.frontiersin.org/journal/immunology)
  • Juan C. Baena, Division of Oncology, Department of Medicine, Fundacion Valle del Lili, ICESI University, Cali, Colombia
  • Juan Sebastian Victoria, Alejandro Toro-Pedroza, Cristian C. Aragon, Joshua Ortiz-Guzman, Juan Esteban Garcia-Robledo, David Torres, Lady J. Rios-Serna, Ludwig Albornoz, Joaquin D. Rosales, Carlos A. Canas, Gustavo Adolfo Cruz-Suarez, Felipe Ocampo Osorio, Tania Fleitas, Ivan Laponogov, Alexandre Loukanov, Kirill Veselkov.

References:

[1] NewsRx. Data on Cancer Gene Therapy Discussed by Researchers at ICESI University (Smart CAR-T Nanosymbionts: archetypes and proto-models). Biotech Week. August 27, 2025; p 15.

[2] Frontiers in Immunology, 2025,16.

Read more